United States Drug Patent 9,138,432: Claim Scope, Exclusivity, Litigation Risk, and Iloperidone Patent Landscape

U.S. Patent No. 9,138,432 protects a dose-adjustment method for reducing QT-prolongation risk in schizophrenia patients treated with iloperidone. The central limitation is conditional dosing: 24 mg/day when the patient is not receiving fluoxetine and 12 mg/day when the patient is receiving fluoxetine. The claim is directed to a treatment method, not to iloperidone itself, a tablet composition, or a manufacturing process.

The patent’s commercial significance depends on whether a generic applicant’s proposed labeling instructs physicians to use the claimed fluoxetine-specific dose reduction. The patent does not prevent all iloperidone sales or all treatment with iloperidone. Its practical reach is narrower and concentrates on the approved dosing instructions for patients taking fluoxetine or another strong CYP2D6 inhibitor.

What does U.S. Patent 9,138,432 claim?

Claim 1 requires all of the following elements:

Claim element	Required showing
Patient population	A patient being treated for schizophrenia
Active drug	Iloperidone
Therapeutic objective	Decreasing the risk of QT prolongation
No-fluoxetine branch	Administering 24 mg/day when the patient is not being treated with fluoxetine
Fluoxetine branch	Administering 12 mg/day when the patient is being treated with fluoxetine
Causation language	The dose is selected “if, and because” of the patient’s fluoxetine-treatment status

The claim is therefore a conditional method-of-treatment claim. It requires a relationship between the patient’s medication status and the iloperidone dose. A generic product that merely contains iloperidone would not inherently practice the claim. Infringement would generally require use of the drug in the claimed clinical manner, or labeling that induces such use.

The claim is also treatment-intent dependent. The stated purpose is reducing QT-prolongation risk in a schizophrenia patient. A use of iloperidone for a different purpose, in a different disease, or without the claimed dose relationship would not necessarily satisfy every limitation.

How does the fluoxetine dose adjustment operate?

Iloperidone is metabolized in part through CYP2D6 and CYP3A4 pathways. Fluoxetine is a strong CYP2D6 inhibitor. Inhibition of iloperidone metabolism can increase exposure and may increase cardiac repolarization risk, including QT prolongation. The FDA-approved Fanapt label therefore instructs that the iloperidone dose should be reduced by one-half when administered with strong CYP2D6 inhibitors such as fluoxetine or paroxetine (FDA, 2024).

The patent converts that pharmacokinetic relationship into a dosing method:

Patient medication status	Claimed iloperidone dose
No fluoxetine	24 mg/day
Receiving fluoxetine	12 mg/day

The claim does not require a measured QT interval, a CYP2D6 genotype, a plasma concentration, or a demonstrated adverse event. The claimed trigger is the presence or absence of fluoxetine treatment, coupled with the specified iloperidone dose and the stated risk-reduction purpose.

What is the legal scope of the “if, and because” language?

The phrase “if, and because” adds a causation requirement. The dose must be selected because the patient is, or is not, being treated with fluoxetine. A physician who happens to administer 12 mg/day to a patient taking fluoxetine may present a weaker infringement case if the dose was chosen for an unrelated reason.

In practice, causation can be established through:

Product labeling;
Prescribing protocols;
Electronic medical-record instructions;
Pharmacy communications;
Clinical guidelines;
Physician testimony;
Dose-adjustment software; and
Generic labeling that expressly instructs the claimed dose reduction.

The claim does not require that fluoxetine be the only medication affecting iloperidone exposure. A patient could be taking other drugs, provided the fluoxetine-dependent dosing relationship remains present.

The claim also has a two-branch structure. Both branches describe the claimed regimen, but a commercial infringement case would usually focus on the 12 mg/day branch because it is more distinctive and more closely tied to the FDA dosing warning.

What does Patent 9,138,432 not cover?

U.S. Patent 9,138,432 does not, based on the supplied claim, cover:

Iloperidone as a chemical compound;
A composition containing iloperidone;
A particular tablet strength or excipient system;
A manufacturing process for iloperidone;
All treatment of schizophrenia with iloperidone;
All treatment with 24 mg/day;
All treatment with 12 mg/day;
A patient taking another CYP2D6 inhibitor without fluoxetine;
A patient who is not being treated for schizophrenia; or
A method requiring CYP2D6 genotyping.

The absence of a formulation limitation makes the claim relevant to immediate-release tablets, capsules, or other dosage forms if the full clinical dosing method is practiced. The absence of a genotype limitation also distinguishes the claim from pharmacogenomic patents directed to CYP2D6 metabolizer status.

What is the Orange Book status of U.S. Patent 9,138,432?

U.S. Patent 9,138,432 is associated with the Fanapt, or iloperidone, regulatory product and is relevant to the Orange Book patent landscape for the drug. Orange Book relevance is determined by whether the patent claims an approved drug substance, drug product, or method of use and whether the patent is timely listed by the NDA holder (FDA, 2024a).

A method-of-use listing generally creates a Paragraph IV issue for a generic applicant only if the proposed labeling would encourage use covered by the listed patent. A generic applicant may seek approval with a section viii statement that carves out the patented use, but that strategy is difficult where the patented method corresponds to a core dosing instruction in the FDA label.

The principal regulatory question is whether the FDA-approved iloperidone labeling contains the 24 mg/day and 12 mg/day instructions in a manner that overlaps the patent’s use code. The Fanapt label includes dose adjustment for strong CYP2D6 inhibitors, including fluoxetine and paroxetine (FDA, 2024). That overlap increases the likelihood that an abbreviated new drug application would address the patent through a Paragraph IV certification, a section viii carve-out, or both, depending on the listed use code and the proposed labeling.

When does U.S. Patent 9,138,432 lose exclusivity?

Patent 9,138,432 issued on September 22, 2015. Its statutory term is generally calculated from the relevant nonprovisional application filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension. The patent is not the original compound patent for iloperidone. Its exclusivity is therefore separate from the basic chemical and formulation patent history.

Event	Date or status
U.S. patent number	9,138,432
Issue date	September 22, 2015
Patent type	Method of treatment
Active ingredient	Iloperidone
Covered condition	Schizophrenia
Key interaction	Fluoxetine-mediated CYP2D6 inhibition
Core dose adjustment	24 mg/day to 12 mg/day
Expected term basis	Twenty years from the applicable nonprovisional filing date, subject to adjustment
Regulatory relevance	Fanapt method-of-use dosing

A precise expiration date should be taken from the USPTO Patent Center record because patent-term adjustment can change the nominal expiry date. FDA marketing exclusivity and patent exclusivity are separate. The end of FDA exclusivity does not terminate the patent, and patent expiration does not necessarily end all regulatory exclusivity.

Which patents compete with Patent 9,138,432 in the iloperidone estate?

The iloperidone estate has historically included several patent categories:

Compound and core pharmaceutical patents

Earlier patents covered iloperidone as a chemical entity and its antipsychotic use. Those patents created the original branded-product exclusivity but are distinct from the later dose-adjustment claim.

Formulation and dosage-form patents

Formulation patents may cover:

Tablet compositions;
Solid-state forms;
Dissolution profiles;
Stability characteristics;
Specific dose strengths; and
Manufacturing processes.

Those patents can create barriers even after a method-of-use patent expires. Their enforceability depends on the exact generic product and on whether the generic applicant certifies that its product does not infringe.

Pharmacokinetic and metabolism patents

Other patents in the broader estate may address CYP2D6 metabolism, drug-drug interactions, metabolizer phenotypes, or dose selection. These claims may overlap commercially with Patent 9,138,432 but differ legally because they may require genetic testing, plasma exposure measurements, or a broader set of CYP2D6 inhibitors.

Method-of-use patents

Patent 9,138,432 belongs to this category. Its commercial value comes from attaching patent protection to an FDA-recognized dosing adjustment rather than to the active ingredient itself.

What generic entry risks exist for iloperidone?

A generic applicant faces three principal pathways.

Paragraph IV challenge

The applicant may certify that Patent 9,138,432 is invalid, unenforceable, or not infringed. The NDA holder may then file an infringement action under the Hatch-Waxman framework. The litigation can delay approval for the statutory stay period, subject to the case’s procedural posture and FDA approval requirements.

The most likely invalidity arguments would target:

Obviousness based on known CYP2D6 inhibition by fluoxetine;
Obviousness of halving the iloperidone dose;
Lack of written description for the exact conditional regimen;
Lack of enablement;
Indefiniteness of “decreasing a risk” or “because”; and
Whether the claimed dose is adequately tied to the stated clinical objective.

The strongest patentability issue is likely obviousness. A challenger would argue that the Fanapt label and pharmacokinetic literature already taught dose reduction with strong CYP2D6 inhibitors. The patent owner would respond that the claimed regimen identifies a specific dose, patient context, and QT-risk objective, and that the prior art did not establish the claimed combination with sufficient predictability.

Section viii carve-out

The applicant may attempt to omit the patented method from its labeling. This approach is commercially viable only if the unpatented label can be drafted without recommending or encouraging the 12 mg/day fluoxetine-related dose reduction.

A carve-out is more difficult when the patented dosing instruction is integrated into the core safety information. FDA may require safety language that overlaps the patented use, creating a “skinny label” dispute.

Non-infringing launch after patent expiry

The applicant may wait for patent expiry or for a final court determination. This route avoids Paragraph IV litigation but delays market entry and permits the brand to retain the relevant indication during the remaining patent term.

How strong is the patent estate for Patent 9,138,432?

The patent has meaningful commercial relevance but a narrower legal perimeter than a compound or composition patent.

Strength factor	Assessment
Link to FDA labeling	Strong, because the label recognizes dose reduction with strong CYP2D6 inhibitors
Product coverage	Limited; the claim does not cover iloperidone itself
Clinical specificity	Strong; the claim identifies schizophrenia, iloperidone, fluoxetine status, and precise doses
Design-around potential	Moderate; a generic may attempt label carving or avoid inducing the patented use
Obviousness exposure	Material, because CYP2D6 inhibition and dose reduction may have been known
Enforcement target	Labeling, prescribing instructions, and induced clinical use
Biosimilar relevance	None; iloperidone is a small-molecule drug
Manufacturing barrier	None apparent from the supplied claim
Geographic scope	United States only

The claim’s strongest feature is its alignment with a clinically necessary dose adjustment. Its main vulnerability is that the underlying interaction between fluoxetine and CYP2D6-mediated metabolism may have been predictable from existing pharmacology and product-label information.

What patent litigation affects iloperidone generic entry?

A Paragraph IV filing directed to Fanapt can generate litigation over listed method-of-use and formulation patents. For Patent 9,138,432, the central disputes would likely involve whether the proposed generic label induces the claimed fluoxetine-specific regimen and whether the claims are valid over the Fanapt label and pharmacokinetic prior art.

The litigation record should be evaluated for:

The exact patents asserted;
The approved generic label;
Any stipulated infringement position;
Claim-construction rulings;
Summary-judgment decisions;
Trial findings;
Federal Circuit treatment of method-of-treatment claims; and
Any settlement or license permitting an agreed launch date.

No settlement date, license, or final judgment is established by the claim text alone. Commercial conclusions should not treat a Paragraph IV filing as proof that generic entry will occur before patent expiry.

How does Patent 9,138,432 compare with biosimilar and generic patent risk?

Iloperidone is a small-molecule active ingredient. Biosimilar pathways under the Public Health Service Act do not apply. Generic applicants proceed under section 505(j) of the Federal Food, Drug, and Cosmetic Act through an ANDA.

The relevant barriers are therefore:

Orange Book-listed patents;
Paragraph IV certifications;
Section viii labeling carve-outs;
Formulation patents;
Method-of-use patents;
Exclusivity periods; and
State-level substitution and prescribing practices.

The patent does not create an interchangeability issue comparable to biologics. If an ANDA is approved, substitution and formulary access will depend mainly on state law, payer contracting, price, and whether the generic label preserves the relevant dosing instructions.

What licensing and commercial exposure matter?

A license covering Patent 9,138,432 could permit an earlier generic launch, but the existence and terms of any license must be established from a settlement agreement, SEC filing, court filing, or other primary record. Royalty rates, launch dates, authorized-generic provisions, and covenants not to sue materially affect valuation and cannot be inferred from the claim.

Commercial exposure is concentrated in branded Fanapt revenue attributable to schizophrenia treatment and in the ability to preserve the branded dosing label. The patent is less valuable as a standalone barrier if generic applicants can obtain approval with a legally effective carve-out. It is more valuable if the FDA-required label necessarily instructs the patented 12 mg/day dose for patients taking fluoxetine.

Key Takeaways

U.S. Patent 9,138,432 is a narrow method-of-treatment patent for iloperidone dosing in schizophrenia.
Claim 1 requires 24 mg/day without fluoxetine and 12 mg/day with fluoxetine.
The claim does not cover iloperidone, tablets, formulations, manufacturing, or all schizophrenia treatment.
Its commercial value comes from overlap with the Fanapt label’s CYP2D6-inhibitor dose adjustment.
A generic applicant’s principal strategies are Paragraph IV litigation, a section viii carve-out, or delayed launch.
The claim has meaningful label-based enforcement potential but faces an obviousness challenge based on known fluoxetine-CYP2D6 pharmacology.
Biosimilar risk is irrelevant because iloperidone is a small-molecule drug.
Patent expiry must be confirmed through USPTO Patent Center because patent-term adjustment can affect the final date.

FAQs About U.S. Patent 9,138,432

Does Patent 9,138,432 prevent generic iloperidone approval?

No. It may delay approval or require a Paragraph IV certification, but it does not automatically block approval after a successful validity or noninfringement determination.

Can a generic omit the fluoxetine dosing instruction?

Possibly, through a section viii carve-out, but only if the resulting labeling does not encourage the patented use and remains acceptable to FDA.

Is paroxetine expressly covered by Claim 1?

The supplied claim names fluoxetine. Paroxetine may be relevant to other claims, the specification, or the FDA label, but it is not expressly required by the quoted Claim 1.

Does the patent require CYP2D6 testing?

No. The supplied claim turns on whether the patient is being treated with fluoxetine, not on CYP2D6 genotype or measured metabolic status.

Is Patent 9,138,432 a formulation patent?

No. It is a method-of-treatment patent directed to dose selection and QT-prolongation risk reduction.

References

U.S. Patent No. 9,138,432. (2015). Methods for reducing the risk of QT prolongation in patients treated with iloperidone. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Fanapt (iloperidone) prescribing information. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
U.S. Patent and Trademark Office. (2024). Patent Center: U.S. Patent No. 9,138,432. U.S. Department of Commerce.
21 U.S.C. § 355. (2024). Federal Food, Drug, and Cosmetic Act, abbreviated new drug applications and patent certifications.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005292246	⤷ Start Trial
Australia	2009291717	⤷ Start Trial
Canada	2582022	⤷ Start Trial
Canada	2736245	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,138,432

Summary for Patent: 9,138,432